Sorrento Therapeutics and ViralClear Enter Into Agreement to Explore Combination Antibody Plus Antiviral Therapy Against COVID-19GlobeNewsWire • 09/30/20
Sorrento Identifies Second 'More Potent' Anti-COVID-19 Antibody For Clinical TestingBenzinga • 09/29/20
Sorrento Releases Preclinical Data for STI-1499 (COVI-Guard™) and STI-2020 (COVI-AMG™), Potent Neutralizing Antibodies Against SARS-CoV-2GlobeNewsWire • 09/29/20
Sorrento Releases Positive Results of Phase 1B Trial of Resiniferatoxin (RTX) In Reduction of OsteoArthritis (OA) Knee PainGlobeNewsWire • 09/28/20
Is the Options Market Predicting a Spike in Sorrento (SRNE) Stock?Zacks Investment Research • 09/25/20
Sorrento Therapeutics Releases Positive Results of Phase 1B Trial of Resiniferatoxin (RTX) Epidural in Cancer Patients with Reported Intractable PainGlobeNewsWire • 09/22/20
Sorrento Surges On FDA Nod For Initiating Clinical Study Of COVID-19 Antibody TreatmentBenzinga • 09/17/20
Sorrento Receives US FDA Clearance to Proceed With Phase 1 Clinical Trial of STI-1499 (COVI-GUARD) Neutralizing Antibody in COVID-19 Positive PatientsGlobeNewsWire • 09/17/20
Monoclonal Antibodies: A Good Place To Be In The Time Of Covid-19 And Stock Market BubblesSeeking Alpha • 09/15/20
Sorrento Secures Exclusive License From Mayo Clinic for Antibody-Drug-Nanoparticle Albumin-Bound Immune Complex (ADNIC) PlatformGlobeNewsWire • 09/14/20